Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DM1157 in Healthy Adults
NCT03490162Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DM1157 in malaria (12 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of Adverse Events, Occurrence of abnormal ECG changes and 3 more. Started Jul 2018; status: terminated.
02
Drugs
DM1157
03
Conditions
malaria
Beyond the preview
Go deeper on NCT03490162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03490162.